RxDoctor Payments Data

Gina Westhoff, MD

Gynecologic Oncology · Portland, ORNPI 1598927261

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,495 of the $15,775 with a category attached, or 60.2%. 17 manufacturers reported payments, led by Merck at 45.5% of the total. Reporting peaked in 2019 at $9,875 and has fallen 57.4% since, to $4,209 in 2025.

$15,775in general payments, 2019–2025

Across 60 payments — averaging $262.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$7K
  • Pfizer$4K
  • Intuitive Surgical$3K
  • AstraZeneca$357
  • Tesaro, Inc.$274
  • Seagen Inc.$211
  • plus $973 from 11 others
$944,619in research payments, 2019–2025

Across 31 payments — averaging $30,472 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$862K
  • Astrazeneca UK Limited$79K
  • Pharmaand GmbH$3K

What the payments were for

  • Speaking & faculty fees$9,49560%
  • Travel & lodging$3,51322%
  • Food & beverage$2,11613%
  • Education$6514%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,775 in reported general payments places this provider in the 75th percentile of 25 gynecologic oncology providers in Oregon.

See all gynecologic oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$69,154
Medicare patients
78
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib18$282,145
EliquisApixaban19$13,358
Dexamethasone24$311
LoperamideLoperamide Hcl13$290
Ondansetron OdtOndansetron20$236
Prochlorperazine Maleate22$218
Oxycodone Hcl37$139
Lidocaine-PrilocaineLidocaine/Prilocaine11$122
Levothyroxine Sodium23$105
Olanzapine13$98
Triamcinolone Acetonide12$64
Ibuprofen15$57
Sertraline Hcl12$30
Lisinopril12$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$357$282,14518 claims
PfizerEliquis$3,991$13,35819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 25 gynecologic oncology providers in Oregon.

Other gynecologic oncology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →